Controlled Trial of Combined Urokinase and Dextran Sulfate Therapy in Patients With Acute Cerebral Infarction

Fujishima, Masatoshi; Omae, Teruo; Tanaka, Kenzo; Iino, Kozo; Matsuo, Osamu; Mihara, Hisashi
July 1986
Angiology;Jul1986, Vol. 37 Issue 7, p487
Academic Journal
In this multiinstitute cooperative study, 143 patients were treated with either urokinase (UK) or combination of urokinase and dextran sulfate (UK-DS) within one to seven days following acute onset of cerebral thrombotic infarction. Of these, 81 randomized cases received a single dose of UK (2.83 × 105 units) by six-hour intravenous drip infusion and the remaining 62 received a combined dose of UK (2.84 × 105 units) and DS (3000mg) for only one day. Moderate to marked clinical improvements assessed during the seven-day study period were observed in 30.9% of the patients treated with UK and in 61.3% of those with UK-DS, the latter being significantly higher. Hemorrhagic phenomena appeared in 3.2% of the cases treated with UK-DS and in none of those with UK alone, but mortality was 1.6% in the former and 2.5% in the latter. UK-DS produced a prompt and sustained increase in plasma fibrinolytic activity with transient and relatively minor disturbance of the blood coagulation system. The results indicate that combined therapy with UK and DS is more effective than UK alone for acute cerebral thrombotic infarction.


Related Articles

  • Streptokinase : A novel clot buster. Vaishnavi, B.; Mohanasrinivasan, V.; Subathra Devi, C. // Journal of Pharmacy Research;Oct2011, Vol. 4 Issue 10, p3784 

    The leading cause of death in the world is coronary heart diseases. About 7.1 million deaths were attributed to ischemic heart disease in 2001 out of which 80% were in relatively poor countries. According to World Health Organisation (WHO) cardiovascular disease caused over 18 million deaths in...

  • streptokinase.  // Royal Society of Medicine: Medicines;2002, p511 

    This article presents information on streptokinase, a fibrinolytic drug. Streptokinase is used therapeutically as a fibrinolytic drug because it has the property of breaking up blood clots. It is used rapidly in such serious conditions as venous thrombi, pulmonary embolism and myocardial infarction.

  • TREATMENT OF CHRONIC THROMBOEMBOLISM WITH ARVIN, ORAL FIBRINOLYTICS AND STANDARD ANTICOAGULANTS. Kounis, Nicholas G.; Evans, W. Howel // Vascular Surgery;Mar/Apr1977, Vol. 11 Issue 2, p68 

    In five patients suffering from recurrent deep venous thrombosis and pulmonary embolism, a therapeutic combination was applied including Arvin, Fearnley's regime and standard anticoagulants. In two patients complete remission of the disease seemed to he achieved during the following two years....

  • Impact of the therapy by renin–angiotensin system targeting antihypertensive agents perindopril versus telmisartan on prothrombotic state in essential hypertension. Remková, A.; Kratochvíl'ová, H.; Ďurina, J. // Journal of Human Hypertension;May2008, Vol. 22 Issue 5, p338 

    The aim of the study was to investigate the effect of therapy by perindopril or telmisartan on endothelial/platelet function and on coagulation/fibrinolysis in 20 and 16 hypertensive patients, respectively. The measurements were carried out before and after 1 month of therapy. Both systolic...

  • The Urokinase Receptor System, A Key Regulator at the Intersection between Inflammation, Immunity, and Coagulation. Del Rosso, Mario; Margheri, Francesca; Serratì, Simona; Chillà, Anastasia; Laurenzana, Anna; Fibbi, Gabriella // Current Pharmaceutical Design;6/30/2011, Vol. 17 Issue 19, p1924 

    The urokinase plasminogen activator (uPA) and its receptor (uPAR) provide a cell surface integrated multimolecular complex that exerts pleiotropic functions influencing the development of inflammatory, immune, coagulation and fibrinolytic responses. Here we review the evidences indicating a role...

  • Urokinase: Restoring circulation without surgery. Borkowski-Weller, Diane M.; Nagle, Sigrid // RN;Oct90, Vol. 53 Issue 10, p44 

    Presents information on the use of urokinase for the treatment of blood clot. Chemical composition of urokinase; Cost of undergoing a urokinase treatment; Advantages of urokinase treatment over streptokinase.

  • Urokinase. Sherry, Sol // Annals of Internal Medicine;Sep68, Vol. 69 Issue 3, p415 

    Describes the development of urokinase, a thrombotic agent obtained from human urine. Effect of the intravenous administration of the agent; Capability of urokinase-induced states of accelerated thrombolytic activity in inciting the lysis of thrombi; Complications of the therapy.

  • fibrinolytic (Major drug group).  // Royal Society of Medicine: Medicines;2002, p246 

    This article presents information on fibrinolytic or thrombolytic drugs, which break up or disperse thrombi of blood clots. Thrombolytic drugs work by activating the breaking down of the protein fibrin, which is the main constituent of many blood clots. Fibrinolytic can be used in serious...

  • Secondary Prevention of Myocardial Infarction: Beneficial Effect of Combining Oral Anticoagulant Plus Aspirin. Altman, Raul; Rouvier, Jorge; Scazziota, Alejandra // Clinical & Applied Thrombosis/Hemostasis;Jul2000, Vol. 6 Issue 3, p126 

    Describes strategies for the secondary prevention of myocardial infarction. Antithrombotic agents most frequently used; Inhibitory effects of antithrombotic agents on thrombin generation or platelet function; Factors involved in the first step in the extrinsic coagulation reactions.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics